In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at least some of its products. The surcharge came following the firm's disclosure of approximately $40 million in tariff-related revenue headwinds for 2025.

University of Chicago spinout OrisDx said Tuesday that it has raised $4 million in seed funding and it will use the money to support the launch of its saliva-based molecular test for oral cancers.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.

PinkDx, Inc., an early-stage company focused on positively impacting the health of women throughout their life journey, today announced that it has completed a second close of its previously announced Series A financing, raising an additional $5 million, including from new investors Blue Venture Fund, Sandbox Clinical Ventures and BEVC. This brings the total raised in the upsized round to $45 million. The funding will help PinkDx further advance its first test, which is intended to clarify diagnosis for women presenting with a potential gynecologic cancer.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Edwards Lifesciences' Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.

Scientific instruments maker Agilent Technologies has promoted Padraig McDonnell to CEO-elect and chief operating officer. He will become president and CEO in May, and will also join the company’s board of directors at that time.

QuidelOrtho announced today that it terminated President and CEO Douglas Bryant, effective immediately.

Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL.